Kazia Therapeutics Announces Preliminary Results From First Patient In Phase 1b Trial Evaluating Combination Regimen Of Paxalisib, Pembrolizumab, And Standard Chemotherapy After Completing Cycle 1 Of Dosing

Kazia Therapeutics (NASDAQ:KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters.